About Lonza
Lonza is a company based in Basel (Switzerland) founded in 1897 was acquired by SBI Mutual Fund in February 2024. Lonza has raised $100 thousand across 6 funding rounds from investors including SBI Mutual Fund, European Union and ALSA Ventures. The company has 18,690 employees as of December 31, 2024. Lonza has completed 11 acquisitions, including Capsugel, InterHealth Nutraceuticals and Lonza. Lonza offers products and services including Integrated Biologics, Advanced Synthesis, and Specialized Modalities. Lonza operates in a competitive market with competitors including Pharmaron, Pfizer, Boehringer Ingelheim, LabConnect and Dotmatics, among others.
- Headquarter Basel, Switzerland
- Employees 18690 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Lonza Group Ag
-
Annual Revenue
$8.24 B (USD)-0.65as on Dec 31, 2025
-
Net Profit
$1.2 B (USD)49.21as on Dec 31, 2025
-
EBITDA
$2.55 B (USD)31.87as on Dec 31, 2025
-
Total Equity Funding
$100 K (USD)
in 6 rounds
-
Latest Funding Round
$100 K (USD), Seed
Nov 25, 2023
-
Investors
SBI Mutual Fund
& 4 more
-
Employee Count
18690
as on Dec 31, 2024
-
Investments & Acquisitions
Capsugel
& 10 more
-
Acquired by
SBI Mutual Fund
(Feb 15, 2024)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Lonza
Lonza is a publicly listed company on the SIX with ticker symbol LONN in Switzerland, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Lonza
Lonza offers a comprehensive portfolio of products and services, including Integrated Biologics, Advanced Synthesis, and Specialized Modalities.
End-to-end development and manufacturing for biologics
Services for small molecules and highly potent APIs
Development for cell, gene, and mRNA technologies
People of Lonza
Unlock access to complete
Funding Insights of Lonza
Lonza has successfully raised a total of $100K across 6 strategic funding rounds. The most recent funding activity was a Seed round of $100 thousand completed in November 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Lonza
Lonza has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include SBI Mutual Fund, European Union and ALSA Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment in biotechnology companies for novel therapeutics is managed.
|
Locked | Locked | Locked | |
|
AI startup acceleration and networking services are offered globally.
|
Locked | Locked | Locked | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked |
Investor details for Lonza
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Lonza
Lonza has strategically engaged in corporate development activities, having acquired 11 companies. Notable acquisitions include Capsugel, InterHealth Nutraceuticals and Lonza.
Investment portfolio details for Lonza
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Provider of cryopreserved hepatocytes for research purposes
|
Locked | Locked | 2012 | Locked | |
|
Antibody-drug conjugate technology platform is developed for cancer therapies.
|
Locked | Locked | 2010 | Locked | |
|
Viral vectors for gene therapy applications are manufactured.
|
Locked | Locked | 2009 | Locked |
Complete acquisition details for Lonza
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Lonza
Detailed financials for Lonza
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Lonza Comparisons
Peer comparison for Lonza
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Lonza
Lonza operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Pharmaron, Pfizer, Boehringer Ingelheim, LabConnect and Dotmatics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Drug discovery and development services for small molecules are provided.
|
|
| Locked | Locked | Locked |
Pharmaceutical products for treating multiple diseases are provided.
|
|
| Locked | Locked | Locked |
Generic drugs and clinical research services are provided globally.
|
|
| Locked | Locked | Locked |
Laboratory testing, clinical trial research, and biopharma services are provided.
|
|
| Locked | Locked | Locked |
AI powered scientific data management and workflow automation solutions
|
Detailed competitors of Lonza
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Lonza
Complete news archive for Lonza
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Lonza
Lonza was founded in 1897 and raised its 1st funding round 113 years after it was founded.
Lonza is headquartered in Basel, Switzerland. It is registered at Basel, Basel-stadt, Switzerland.
Pierre Alain Ruffieux is the current CEO of Lonza.
Lonza is a funded company, having raised a total of $100K across 6 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Lonza is 18,690.
Annual revenue of Lonza is $8.24B as on Dec 31, 2025.
Provider of CDMO services to pharma, biotech, and specialty ingredient markets. The company offers a complete range of development and manufacturing services for fine chemicals, advanced intermediates, active pharmaceutical ingredients (APIs), biologics, and functional ingredients. They claim to offer synergies between chemical synthesis and biotechnology to enable the production of tailor-made intermediates and APIs for use as pharmaceuticals, biotherapies, nutraceuticals, and cosmetics. Their proprietary platforms and development technologies such as GS Gene enable them to offer customized biological and chemical manufacturing solutions. In 2022, the company recorded annual revenues of 6.52B and a net profit of 1.27B.
Lonza offers Integrated Biologics, Advanced Synthesis, and Specialized Modalities.
Yes, Lonza is publicly traded on SIX under the ticker symbol LONN.
Lonza has made 11 acquisitions, including Capsugel, InterHealth Nutraceuticals, and Lonza.
Lonza has 5 investors. Key investors include SBI Mutual Fund, European Union, ALSA Ventures, U.S. Department of Defense, and Upekkha.
The ticker symbol of Lonza is LONN on SIX.